Pharmaceutical - Cardio-vascular, Oncology

Filter

Current filters:

Cardio-vascularOncology

Popular Filters

1 to 25 of 37 results

Added indications recommended by EMA/CHMP

Added indications recommended by EMA/CHMP

27-06-2014

Along with backing for approval for six news drugs issued at the late June meeting of the European Medicines…

AvastinBayerBristol-Myers SquibbCardio-vascularEliquisEuropeEyleaKalydecoOncologyOphthalmicsPfizerPharmaceuticalRare diseasesRegulationRocheVertex Pharmaceuticals

AstraZeneca stresses confidence in independence, highlighting strong R&D pipeline

15-05-2014

Anglo-Swedish pharma major AstraZeneca, the subject of the controversial takeover attempt by Pfizer,…

AstraZenecaCardio-vascularMergers & AcquisitionsMetabolicsOncologyPharmaceuticalResearchRespiratory and Pulmonary

Merck starts roll-out of BLA for MK-3475; vorapaxar FDA panel review

Merck starts roll-out of BLA for MK-3475; vorapaxar FDA panel review

14-01-2014

US drug giant Merck & Co says it has started a rolling submission to the US Food and Drug Administration…

Cardio-vascularMerck & CoMK-3475North AmericaOncologyPharmaceuticalRegulationUSAvorapaxarZontivity

Catalyst-rich period ahead for key trial results from BioLineRx

09-12-2013

Israeli drug developer BioLineRx is entering a catalyst-rich phase over the next 12 months, which will…

Anti-viralsBioLineRxBL-1040BL-8020BL-8040Cardio-vascularFinancialOncologyPharmaceuticalResearch

EMA Pharmacovigilance unit updates on Iclusig, diacerein and acipimox

EMA Pharmacovigilance unit updates on Iclusig, diacerein and acipimox

09-11-2013

At its November 4-7 meetings, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee…

acipimoxAnti-Arthritics/RheumaticsAriad PharmaceuticalsCardio-vasculardiacereinEuropeIclusigOncologyPharmaceuticalRegulation

FDA approves Bayer’s Adempas; firm accelerates drug candidates

FDA approves Bayer’s Adempas; firm accelerates drug candidates

09-10-2013

The US Food and Drug Administration late yesterday approved Adempas (riociguat), developed by German…

AdempasBayerCardio-vascularcopanlisibfinerenoneNorth AmericaOncologyPharmaceuticalRegulationResearchRespiratory and PulmonaryWomen's Health

Radiopharmaceuticals market to hit a value of $7.9 billion by 2018

21-08-2013

The radiopharmaceuticals market has been forecast to exceed a value of $7.9 billion by 2018, driven by…

Cardio-vascularGlobalMarkets & MarketingNeurologicalOncologyPharmaceutical

Increased breast cancer risk with long-term use of calcium-channel blockers for hypertension

06-08-2013

Long-term use of a calcium-channel blocker to treat hypertension (high blood pressure) is associated…

Cardio-vascularOncologyPharmaceuticalResearch

Developing cancer cures is top priority for Americans, survey shows

05-08-2013

A new survey commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA) shows 86%…

Cardio-vascularHealthcareNorth AmericaOncologyPharmaceuticalResearch

India's NPPA to slash prices of key drugs by up to half

17-06-2013

In India, some key cancer drugs, antibiotics and medicines to treat cardiovascular diseases and tuberculosis…

Asia-PacificCardio-vascularOncologyPharmaceuticalPricing

Abcam in deal with Pfizer to supply compounds to researchers

12-06-2013

UK-based Abcam (AIM: ABC), a producer and distributor of protein research tools, has entered into a license…

AbcamCardio-vascularLicensingNeurologicalOncologyPfizerPharmaceuticalResearch

Negative late-stage trial results for Sanofi's iniparib and otamixaban

03-06-2013

There was disappointing news from French drug major Sanofi (Euronext: SAN) this morning (June 3), as…

BiotechnologyCardio-vasculariniparibOncologyotamixabanPharmaceuticalResearchSanofi

Amgen and Astellas link up on drugs for unmet medical needs in Japan

29-05-2013

World leading independent biotech firm Amgen (Nasdaq: AMGN) has joined forces with Japanese drug major…

AmgenAnti-Arthritics/RheumaticsAsia-PacificAstellas PharmaBiotechnologyCardio-vascularOncologyPharmaceuticalResearch

SOBI gains distribution rights for Megace, Monopril, Cefzil and Duricef from PharmaSwiss

13-02-2013

Swedish Orphan Biovitrum (STO: SOBI) says that it has entered into a distribution agreement with privately-held…

Antibiotics and Infectious diseasesCardio-vascularCefzilDuricefEuropeLicensingMegaceMonoprilOncologyPharmaceuticalPharmaSwissSobiSwedish Orphan Biovitrum

Negative NICE final guidance for Pierre Fabre's Javlor in bladder cancer; fast-track FAD for Eliquis

23-01-2013

In final guidance published (January 23, 2013), UK drugs watchdog the National Institute for Health and…

Bristol-Myers SquibbCardio-vascularEliquisEuropeJavlorOncologyPfizerPharmaceuticalPierre FabrePricingRegulation

Bayer initiates Ph III trail of Xarelto in cardiac event prevention; R&D day presentation

14-11-2012

German drug major Bayer (BAYN: DE) has initiated the Phase III COMPASS study of its oral anticoagulant…

AlpharadinBayerCardio-vascularOncologyOphthalmicsPharmaceuticalResearchStivargaXarelto

News briefs: Auxilium/Pfizer accord; Novartis Signifor and RLX030 developments

08-11-2012

US specialty drugmaker Auxilium Pharmaceuticals' (Nasdaq: AUXL) shares fell 7.2% to $18.60 at close of…

Auxilium PharmaceuticalsBiotechnologyCardio-vascularLicensingNovartisOncologyPfizerPharmaceuticalRare diseasesResearchRLX030SigniforXiaflexXiapex

1 to 25 of 37 results

Back to top